SAN FRANCISCO – Investigators with the HPS2-THRIVE study of Merck & Co. Inc.’s combination drug Tredaptive are implicating niacin as the culprit of severe adverse events in the trial, most of which required hospitalization.
Merck had announced in December 2012 that Tredaptive did not meet the primary endpoint in the trial and that it was discontinuing development and ex-U.S. marketing of the combination of extended-release niacin and the anti-flushing agent laropiprant
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?